Opinion|Videos|May 15, 2024
Evaluating Safety of Novel LDL Management Mechanism
Deepak Bhatt, MD, MPH, MBA, reviews the efficacy and safety data of inclisiran, highlighting its long-term effects and noting that injection site reactions are among the most prominent adverse reactions associated with this medication.
Advertisement
Episodes in this series
Advertisement
Related to this article
These data from CARDIO-TTRansform were presented at HFSA 2026, highlighting positive data from the trial despite its failure to improve cardiovascular mortality.
A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
A recent retrospective analysis presented at HFSA 2026 has demonstrated the association between GLP-1 agonists, weight reduction, and PA pressures.
A new analysis of the SEQUOIA-HCM trial, presented at HFSA 2026, demonstrates aficamten’s association with improvements to an understudied aspect of the condition.
A recent network meta-analysis presented at HFSA 2026 displays finerenone’s favorable safety profile and comparatively greater reduction of acute kidney injury risk.
A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
Advertisement
Advertisement
Trending on HCPLive
1
Eplontersen Fails to Achieve Primary Endpoint, Improves KCCQ and 6MWT in ATTR-CM
2
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
3
Efruxifermin Shows Durable Antifibrotic Response in MASH Through 96 Weeks
4
Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF
5